Welcome to our dedicated page for CERo Therapeutics news (Ticker: CERO), a resource for investors and traders seeking the latest updates and insights on CERo Therapeutics stock.
CERo Therapeutics Holdings Inc. (CERO) is a clinical-stage biopharmaceutical company advancing novel engineered T-cell therapies that combine innate phagocytic mechanisms with adaptive immune precision. This dedicated news hub provides investors and industry stakeholders with comprehensive updates on the company's scientific progress and operational developments.
Our curated collection features official press releases, clinical trial milestones, and strategic partnership announcements. Users will find verified information spanning CERo's CER-T platform advancements, regulatory submissions, preclinical data disclosures, and manufacturing innovations - all essential for tracking this immunotherapy pioneer's trajectory.
The resource prioritizes timely updates on key focus areas including target validation studies, IND-enabling research, and technology licensing agreements. Each entry maintains technical accuracy while remaining accessible to both professional investors and those new to cellular immunotherapy concepts.
Bookmark this page for centralized access to CERo's evolving story in cancer treatment innovation. Check regularly for updates on therapeutic pipeline developments, peer-reviewed publication highlights, and critical business updates that shape the company's position in the competitive oncology landscape.
CERo Therapeutics (NASDAQ: CERO) has received positive FDA review on Chemistry, Manufacturing and Controls (CMC) amendment to its IND for CER-1236, marking the final commitment before initiating patient dosing. This development reduces manufacturing timeline by approximately one week.
The company remains on schedule to begin dosing initial subjects in first half of 2025 for their Phase 1/1b clinical trial targeting relapsed/refractory measurable residual disease positive acute myeloid leukemia. The study will evaluate safety and preliminary efficacy through a two-part process: dose escalation followed by expansion phase.
Additionally, CERo's abstract has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) conference, scheduled for May 30-June 5 in Chicago.
CERo Therapeutics Holdings (Nasdaq: CERO) has secured a manufacturing agreement with the University of California Davis for CER-1236, advancing towards its Phase 1 clinical trial for Acute Myeloid Leukemia (AML). The agreement represents one of the final steps before patient dosing, which is anticipated in the first half of 2025.
The company emphasizes the critical importance of precision and compliance in manufacturing for successful clinical trial development and execution, highlighting UC Davis's leading reputation in this field. This development positions CERo to progress with its innovative immunotherapy program, which focuses on engineered T cell therapeutics utilizing phagocytic mechanisms.
CERo Therapeutics (Nasdaq: CERO) presented encouraging preclinical results for its lead compound CER-1236 in ovarian cancer at the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting. The study demonstrated that CER-1236 effectively treated ovarian cancer cells without generating toxicity in animal models.
Key findings showed T cell engraftment in lymphoid organs following CER-1236 infusion, with no adverse clinical pathology or histopathological evaluations indicating toxicity. The research was presented in a poster titled 'TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity.'
The company plans to initiate Phase 1 trials in AML and expand testing to solid tumors in 2025, noting potential broader applications across cancer types, including Non-Small Cell Lung Cancers (NSCLC).
CERo Therapeutics Holdings (Nasdaq: CERO) has made progress toward initiating its Phase 1 clinical trial for CER-1236 in Acute Myeloid Leukemia (AML) by signing an agreement with CellCarta, a contract research organization (CRO). CellCarta will manage important translational assays, including pharmacokinetics, cytokine secretion, and target detection for the upcoming trial.
The CRO will also handle sample kitting, shipment, and logistics to maintain clinical sample integrity during transport. This partnership represents a significant step as CERo prepares for patient enrollment. The company is also advancing its work in solid tumors, with updates expected in the near term.
CERo Therapeutics Holdings (Nasdaq: CERO) has announced its upcoming presentation of preclinical results for CER-1236 in ovarian cancer at the Society for Immunotherapy of Cancer (SITC) Spring Scientific in San Diego, March 12-14, 2025.
The presentation, scheduled for March 13, 2025, will feature a poster titled 'TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity.' The data will be made available on the company's website at 9:00 AM ET on the same day.
The company is advancing toward launching a Phase 1 trial in AML and has previously presented substantial data in Non-Small Cell Lung Cancer (NSCLC). CERo plans to test CER-1236 in multiple indications including AML, ovarian cancer, and NSCLC in 2025, demonstrating the compound's potential across various cancer types.
CERo Therapeutics Holdings (Nasdaq: CERO) reports significant progress in early 2025, highlighting three major developments. First, the company has strengthened its financial position with a $5 million financing, bringing its cash balance to approximately $8 million. Second, CERo is advancing toward initiating its Phase 1 clinical trial of CER-1236 in AML, expecting to dose the first patient in H1 2025, with plans to expand trials into breast and lung cancers. Third, the company completed a 100:1 reverse stock split and has received additional time from Nasdaq to achieve listing compliance. The company has also completed the conversion of majority preferred shares into common shares, improving its capital structure.
CERo Therapeutics (Nasdaq: CERO) has announced a $5 million public offering priced at-the-market. The offering includes 2,551,020 shares of common stock (or equivalents) and warrants to purchase an equal number of shares at a combined price of $1.96. The warrants will have the same exercise price, be exercisable upon stockholder approval, and expire after 5 years.
The offering, expected to close around February 7, 2025, includes participation from a board member and an institutional investor. A.G.P./Alliance Global Partners is acting as sole placement agent. The company plans to use the proceeds for advancing clinical programs and general corporate purposes.
CERo Therapeutics Holdings (Nasdaq: CERO), an immunotherapy company, announced a one-for-one hundred reverse stock split of its common stock. This split will be effective at 12:01 a.m. Eastern Time on January 8, 2025, and the company's stock will start trading on a split-adjusted basis on Nasdaq from the opening of trading on the same day. The CUSIP number 71902K303 will be assigned to the common stock post-split.
The reverse stock split will reduce the number of outstanding shares from approximately 260 million to 2.6 million. Proportional adjustments will be made to shares awarded under equity incentive plans and the exercise prices of stock options and other equity securities. Additionally, adjustments will be made to preferred stock and warrants.
No fractional shares will be issued; stockholders will receive an additional fraction to round up to the next whole share. Stockholders with shares in book-entry form or through brokers do not need to take any action as the split will be automatically reflected in their accounts.
The reverse stock split ratio is within the range authorized by stockholders at the Autumn 2024 Special Meeting on November 11, 2024. The split aims to increase the market price of CERo's common stock to meet Nasdaq's minimum bid price requirement of $1.00 per share, following a delisting notice due to the stock trading below $0.10 for ten consecutive days.
CERo Therapeutics (Nasdaq: CERO) has appointed Chris Ehrlich as permanent CEO, following his previous role as Interim CEO. The company, focused on engineered T cell therapeutics with phagocytic mechanisms, plans to advance its CER-1236 program with an anticipated IND filing for solid tumors, including ovarian and non-small cell lung cancers, in H1 2025.
Ehrlich brings extensive experience in biotechnology, business development, venture capital, and investment banking. He currently serves as CEO of Launch One Acquisition and has previously led successful mergers including Phoenix Biotech Acquisition with CERo, and Locust Walk Acquisition with eFFECTOR Therapeutics.
CERo Therapeutics (Nasdaq: CERO) has received FDA clearance for its Investigational New Drug Application to begin Phase 1 clinical trials of CER-1236 in acute myelogenous leukemia (AML). The company, focused on developing engineered T cell therapeutics with phagocytic mechanisms, plans to initiate its first-in-human trial in Q1 2025. The treatment represents a novel approach to treating AML, one of the deadliest forms of cancer.
FAQ
What is the current stock price of CERo Therapeutics (CERO)?
What is the market cap of CERo Therapeutics (CERO)?
